Mirae Asset Global Investments
MRSN

Mirae Asset Global Investments’s Mersana Therapeutics MRSN Stock Holding History

Mirae Asset Global Investments’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-193
Closed -$1.5K – 1709
2025
Q3 		$1.5K Hold
193
– – ﹤0.01% 1637
2025
Q2 		$1.43K Buy
193
+28
+17% +$246 ﹤0.01% 1572
2025
Q1 		$1.57K Hold
165
– – ﹤0.01% 1543
2024
Q4 		$6.18K Buy
+165
New +$8.54K ﹤0.01% 1543
2024
Q2 		– Sell
-2,165
Closed -$226K – 2145
2024
Q1 		$226K Buy
+2,165
New +$215K ﹤0.01% 2214
2023
Q3 		– Sell
-2,284
Closed -$187K – 2620
2023
Q2 		$187K Sell
2,284
-279
-11% -$40.8K ﹤0.01% 2367
2023
Q1 		$263K Buy
2,563
+742
+41% +$104K ﹤0.01% 2226
2022
Q4 		$267K Buy
1,821
+470
+35% +$79.4K ﹤0.01% 2200
2022
Q3 		$228K Buy
1,351
+446
+49% +$72.5K ﹤0.01% 2285
2022
Q2 		$104K Buy
+905
New +$85.1K ﹤0.01% 2301

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $135M AUM 36.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mirae Asset Global Investments's MRSN Position: Q4 2025 in Review

Mirae Asset Global Investments sold out of Mersana Therapeutics (MRSN) in Q4 2025, closing a stake of 193 shares — an estimated $1.5K sold.

Mirae Asset Global Investments first reported a position in MRSN in Q2 2022 and held it in 10 quarters. The position peaked at $267K in Q4 2022. 51 funds tracked by Wall St. Rank hold MRSN as of Q4 2025.

  • Mirae Asset Global Investments reported no remaining Mersana Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Mirae Asset Global Investments sold 193 Mersana Therapeutics shares in Q4 2025, an estimated $1.5K.
  • Mirae Asset Global Investments first reported a position in Mersana Therapeutics in Q2 2022 and held it in 10 quarters.
  • Mirae Asset Global Investments's Mersana Therapeutics position peaked at $267K in Q4 2022.
  • 51 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2025.

Based on Mirae Asset Global Investments's 13F filing for Q4 2025, filed 26 Jan 2026.